Endocyte Reports First Quarter Financial Results and Provides Clinical Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Endocyte (ECYT) Removed from Wedbush's Best Ideas List
May 5, 2014 10:21 AM EDTWedbush maintained an Outperform rating on Endocyte (NASDAQ: ECYT) but removed the stock from its Best Ideas List. Its price target was reduced to $26.00 (from $65.00).
Analyst Gregory R. Wade said, "The Data Safety... More
Baird Downgrades Endocyte (ECYT) to Neutral
May 2, 2014 10:17 AM EDTBaird downgraded Endocyte (NASDAQ: ECYT) from Outperform to Neutral with a price target of $8.00.
For an analyst ratings summary and ratings history on Endocyte click here. For more ratings news on Endocyte click here.
Shares of Endocyte closed at $17.38 yesterday.
... MorePiper Jaffray Downgrades Endocyte (ECYT) to Neutral
May 2, 2014 9:03 AM EDTPiper Jaffray downgraded Endocyte (NASDAQ: ECYT) from Overweight to Neutral with a price target of $13.50.
For an analyst ratings summary and ratings history on Endocyte click here. For more ratings news on Endocyte click here.
Shares of Endocyte closed at $17.38 yesterday.
... MoreEndocyte, Inc. (ECYT) Tops Q1 EPS by 5c; Reports Halt of PROCEED Trial (MRK)
May 2, 2014 8:02 AM EDTEndocyte, Inc. (NASDAQ: ECYT) reported Q1 EPS of ($0.09), $0.05 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $17.3 million versus the consensus estimate of $15.07 million.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and... More
